Skip to main content
TXG logo

TXG · 10x Genomics, Inc. · Documents

Track TXG — free
$51.80 -5.58 (-9.72%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$6.81B
Shares
131.53M
Volume · Nov 20 3.23M Avg daily vol (3M) 3.36M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $642.82M up 5.2% 10-K filed Feb 13, 2026 Quarterly report FY2026 Q3 Revenue $150.67M up 1.1% 10-Q filed Nov 6, 2026 Latest results Raises 2026 revenue guidance amid 1% quarterly growth 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows 1% as gross margin rises to 75%

10x Genomics, Inc. reported products and services revenue of $150.2 million for the three months ended September 30, 2026, up 1%, while gross margin rose to 75%. It agreed to acquire Proteintech Genomics, Inc. for $6.1 million.

Revenue $150.67M ▲ 1.1% Net loss $19.43M Diluted EPS -$0.15
Read from the MD&A section
4 source passages
10x Genomics, Inc. Products and services revenue increased $2.2 million, or 1%, to $150.2 million for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025. Gross margin increased to 75% for the three months ended September 30, 2026 as compared to 67% for the three months ended September 30, 2025. On June 8, 2026, we entered into a stock purchase agreement (“SPA”) to acquire 100% of the outstanding shares of common stock of Proteintech Genomics, Inc. (“PTG”), a division of Proteintech Group, Inc. (“Proteintech”), for $6.1 million in cash. Open the document at this passage
Nov 5
Earnings call
Raises 2026 Outlook and ATERRA Shipment Plan to 50

10x Genomics reported third-quarter revenue of $150.7 million, up 1%, raised its 2026 revenue outlook to $625 million to $635 million and expects approximately 50 ATERRA instruments by year-end, up from approximately 40.

4 source passages
Earlier today, 10x Genomics released financial results for the third quarter ended September 30, 2026. Revenue for the third quarter was $150.7 million, representing 1% growth over the prior year period. Turning to our outlook for the rest of the year, we are raising our full-year outlook and now expect 2026 revenue to be in the range of $625 million to $635 million. As a result, we now expect to ship approximately 50 ATERRA instruments by year-end, up from our previous expectation of approximately 40. Open the document at this passage
Nov 5
Current report 8-K
Raises 2026 revenue guidance amid 1% quarterly growth

10x Genomics, Inc. reported third-quarter 2026 revenue of $150.7 million, up 1% year over year, and net loss of $19.4 million; it raised full-year revenue guidance to $625 million to $635 million.

Financial results
4 source passages
10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026. Revenue was $150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025. Net loss was $19.4 million for the third quarter of 2026, as compared to net loss of $27.5 million for the corresponding prior year period. 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $625 million to $635 million, versus the previous range of $610 million to $630 million. Open the document at this passage
Nov 2
Current report 8-K Events of Oct 28
Board appoints Ansuman Satpathy and Joseph Gilliam as Class III directors

10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors effective October 28, 2026. Gilliam was also named Audit Committee Chair on October 30, 2026, with a $25,000 annual retainer.

Director or officer change, or executive pay
2 source passages
On October 28, 2026, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Ansuman Satpathy and Joseph Gilliam to the Board of Directors as Class III directors effective immediately On October 30, 2026, Mr. Gilliam was appointed Chair of the Audit Committee of the Board of Directors, for which he shall receive an annual retainer of $25,000 (prorated as necessary). Open the document at this passage
Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $151.04M ▼ 12.6% Net loss $17.93M Diluted EPS -$0.14
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $150.84M ▼ 2.6% Net loss $13.47M Diluted EPS -$0.10
Apr 24
Proxy statement DEF 14A Meeting Jun 4, 2026
Proxy statement AI summary on its way
Feb 13
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $642.82M ▲ 5.2% Net loss $43.54M Diluted EPS -$0.35
2025
Feb 13
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $610.79M ▼ 1.3% Net loss $182.63M Diluted EPS -$1.52
2024
Showing 1–50 of 134 documents
Key facts CIK 1770787 CUSIP 88025U109 13F (30d) 482 filings 441 filers Visit website Investor relations